Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, ...
Whether your screen is made up of your personal favorite data points or are imported from Morningstar’s pre-defined screens, you can control the data you see and the order in which columns are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results